This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Respected Neuropathologist Appointed New Editor-in-Chief Of The American Journal Of Pathology

PHILADELPHIA, January 3, 2013 /PRNewswire/ --

The editorial leadership of The American Journal of Pathology ( AJP) passed to the direction of esteemed neuropathologist Kevin A. Roth, M.D., Ph.D. on January 1, 2013.

Dr. Roth holds the Robert and Ruth Anderson Endowed Chair in Pathology at the University of Alabama at Birmingham (UAB).  Involved in experimental pathology research for nearly 30 years, he published his first paper in AJP while an M.D., Ph.D. student at Stanford University. Dr. Roth also possesses extensive editorial experience, having served as an Associate Editor for AJP since 2003 and as Editor-in-Chief of the Journal of Histochemistry and Cytochemistry from 2006 to 2010.

The AJP is the leading global forum for reporting quality original research on cellular and molecular mechanisms of disease. With over 100 years of history, the Journal is widely read by the pathology community and garners over 30,000 citations to its articles each year (Source: 2011 Journal Citation Reports).  Notably, Dr. Roth is also currently serving as Special Editor of the AJP Centennial Project, a special review series to celebrate the centennial of the American Society for Investigative Pathology (ASIP), which owns AJP.

Dr. Roth has served as a Councilor for ASIP from 2010 to 2012, and is currently the ASIP Vice President. His term as ASIP President begins in 2014. Regarding his editorial appointment, Dr. Roth stated, "It is a special honor to be named the new Editor-in-Chief of The American Journal of Pathology in this centenary year. AJP, the official journal of this esteemed society [ASIP], has historically been one of the most prestigious and frequently cited journals in the field of pathology, and it is my intent to enhance further the quality and recognition of the Journal."

Dr. Roth completed his postdoctoral training at Washington University, where he rose to professor in the Division of Neuropathology, Department of Pathology and Immunology, and in the Department of Molecular Biology and Pharmacology. Dr. Roth moved to UAB in 2002 and served as Director of the Division of Neuropathology until his appointment as Chair of Pathology in 2008.

Dr. Roth, a renowned researcher on the molecular regulation of neuronal cell death, was the founding director of the UAB Comprehensive Neuroscience Center, an interdisciplinary collaboration for neuroscience research, clinical care, and education. The long-term goals of Dr. Roth's own research are to understand the role of cell death in normal nervous system development and its significance in neuropathological conditions including nervous system neoplasia.

Stock quotes in this article: ENL, RUK 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs